The "genetics" of different kinds are awkwardly expensive. This appears to be the one sector which is trading independently of its company performance.
Looks like people forgot to sell those shares, or simply didn't begin selling (but then, why should they, it is a sector which is positive in 2000).
Is it time to restart the tulippomania blowoff with respect to some overextended "bio" & and "gene" companies?
What do you think?
The likes of HGSI, MYGN, MLNM, maybe MAXY, CRA, GLGC, ABGX, NGEN, IMCL etc come to my mind. And what about Trimeris, TRMS?
Many of those stocks have high sales multiples and steep losses, need additional capital, etc... earnings, revenues don't count? |
